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Dietary intervention with extensively hydrolyzed casein formula supplemented with Lactobacillus
rhamnosus GG (EHCF+LGG) accelerates tolerance acquisition in infants with cow’s milk allergy
(CMA). We examined whether this effect is attributable, at least in part, to an influence on the gut
microbiota. Fecal samples from healthy controls (n= 20) and from CMA infants (n= 19) before and
after treatment with EHCF with (n= 12) and without (n= 7) supplementation with LGG were compared
by 16S rRNA-based operational taxonomic unit clustering and oligotyping. Differential feature
selection and generalized linear model fitting revealed that the CMA infants have a diverse gut
microbial community structure dominated by Lachnospiraceae (20.5±9.7%) and Ruminococcaceae
(16.2±9.1%). Blautia, Roseburia and Coprococcus were significantly enriched following treatment
with EHCF and LGG, but only one genus, Oscillospira, was significantly different between infants that
became tolerant and those that remained allergic. However, most tolerant infants showed a
significant increase in fecal butyrate levels, and those taxa that were significantly enriched in these
samples, Blautia and Roseburia, exhibited specific strain-level demarcations between tolerant and
allergic infants. Our data suggest that EHCF+LGG promotes tolerance in infants with CMA, in part, by
influencing the strain-level bacterial community structure of the infant gut.
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Introduction
The prevalence of allergic responses to food has been
experiencing an unprecedented increase in devel-
oped societies, rising by as much as 20% in a recent
10-year period (Branum and Lukacs, 2009; Osborne
et al., 2011; Wang and Sampson, 2011; Prescott et al.,
2013). Genetic variation alone cannot account for a
dramatic increase in disease prevalence over such a
short time frame. Emerging evidence suggests that
twenty-first century environmental interventions,
including widespread antibiotic use, consumption
of a high-fat/low fiber diet, elimination of previously
common enteropathogens (including Helicobacter
pylori and helminthic parasites), reduced exposure
to infectious disease, Caesarean birth, and formula
feeding, may have perturbed the mutually beneficial
interactions established over millions of years of co-
evolution with the bacteria that comprise our
commensal microbiota (Cho and Blaser, 2012). This
dysbiosis can predispose genetically susceptible
individuals to allergic disease (reviewed in ref.
Feehley et al., 2012). Cow’s milk allergy (CMA) is
one of the most common food allergies of infancy
and early childhood with an estimated prevalence of
2–3% worldwide (Sicherer, 2011). We have demon-
strated that dietary management with a formula
containing an extensively hydrolyzed form of the
cow’s milk protein casein (EHCF), supplemented
with the probiotic Lactobacillus rhamnosus GG
(LGG), results in a higher rate of tolerance acquisi-
tion in infants with CMA than in those treated with
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EHCF without supplementation or with other non-
casein-based formulas (Berni Canani et al., 2012,
2013). However, the mechanistic basis for this effect
is not known. We hypothesized that it is attributable,
in part, to an influence of this dietary intervention on
the composition of the gut microbiota. To test this
hypothesis, we performed 16S ribosomal RNA
(rRNA)-based amplicon sequencing and oligotyping
analysis on stool samples collected from healthy
infants and from CMA infants before and after
treatment with EHCF with or without supplementa-
tion with LGG.
Materials and methods
Patient enrollment and sample collection
Infants invited to participate in the study were
referred to a tertiary pediatric allergy center
(Pediatric Food Allergy Unit at the Department of
Translational Medical Science of the University of
Naples ‘Federico II’) for a full diagnostic work-up for
suspected CMA. All patients were still receiving
cow’s milk protein (mainly from formula feeding) at
the time of enrollment and first stool sampling.
The inclusion criteria were infants aged 1–12 months
with a recent strong suspicion of IgE-mediated CMA
but still receiving cow’s milk protein. Diagnosis of
IgE-mediated CMA was based on clinical history, the
results of a double blind placebo-controlled oral food
challenge, and the level of serum-specific anti-cow’s
milk protein IgE (Berni Canani et al., 2011). Patients
administered pre- or probiotic products and/or
antibiotics in the previous 4 weeks, and patients
with a history of cow’s milk-induced anaphylaxis,
eosinophilic disorders of the gastrointestinal tract,
food protein-induced enterocolitic syndrome, con-
comitant chronic systemic diseases, congenital car-
diac defects, active tuberculosis, autoimmune
diseases, immunodeficiency, chronic inflammatory
bowel diseases, celiac disease, cystic fibrosis, meta-
bolic diseases, lactose intolerance, malignancy,
chronic pulmonary diseases or malformations of
the gastrointestinal tract were excluded. Fecal
samples were collected at baseline before diet
therapy from patients with a confirmed diagnosis
of IgE-mediated CMA according to standardized
criteria (Berni Canani et al., 2011). Following the
initial visit, patients were treated by dietary manage-
ment with a commercially available extensively
hydrolyzed casein formula (EHCF, Nutramigen,
Mead Johnson, Rome, Italy) either with or without
supplementation with LGG (at 4.5 × 107–8.5 × 107
colony-forming units per gram of powder (Berni
Canani et al, 2012). A second fecal sample was
obtained after 6 months. Samples obtained from
healthy (non-allergic) infants who visited the study
clinic as part of a vaccination program served as
controls. These subjects were not at risk for atopic
disorders and their clinical history was negative for
any allergic condition. The study was conducted in
accordance with the Declaration of Helsinki and
approved by the Ethics Committee of the University
of Naples ‘Federico II’.
Fecal DNA isolation and 16S rDNA sequencing
Feces were collected and frozen at −20 °C immedi-
ately after excretion. To isolate DNA, 100–300mg of
fecal material was bead beaten before extraction with
the QIAamp DNA stool mini kit (Qiagen, Hilden,
Germany). 16S V4-region amplicon libraries were
produced using previously described primers and
sequenced using the Illumina MiSeq platform (150
bp×2) at Argonne National Laboratory’s Biosciences
Sequencing Core facility (Caporaso et al., 2011).
Bacterial load was determined by quantitative
PCR using a standard curve derived from a plasmid
containing a single copy of the 16S rRNA encoding
gene (Stefka et al., 2014). Sequence data have been
deposited in MG-RAST (http://metagenomics.anl.gov)
under accession numbers 4571868.3–4571924.3 and
project number 10023.
Bioinformatics analysis
Paired end reads were quality trimmed and pro-
cessed for operational taxonomic unit (OTU) cluster-
ing using UPARSE pipeline (Edgar, 2013), set at
0.97% identity cutoff. Taxonomic status was
assigned to the high-quality (o1% incorrect bases)
candidate OTUs using the ‘parallel_assign_taxono-
my_rdp.py’ script of QIIME software (Caporaso et al.,
2010). Multiple sequence alignment and phyloge-
netic reconstruction were performed using PyNast
and FastTree (Caporaso et al., 2010). Phyloseq
package (McMurdie and Holmes, 2013) was used
for the detailed downstream analysis on a rarefied
abundance matrix. This matrix was processed to
remove OTUs containing less than five reads to
reduce the PCR and sequencing based bias; then, the
OTU table was rarified to the minimum numbers of
reads present in the smallest library (3746 reads).
We used the oligotyping pipeline (Eren et al., 2013)
to identify the sub-OTU level differences in the top
five most differentially abundant genera, that is,
Roseburia, Blautia, Coprococcus, Faecalibacterium
and Bifidobacterium, as predicted by Metagenome-
Seq (Paulson et al., 2013).
Statistical analysis
We used MetagenomeSeq (Paulson et al., 2013)
software to determine the differentially abundant
OTUs, families, and genera, present across all
groups. We also used nonparametric Kruskal–Wallis
H-test (post hoc Tukey Kramer tests, Bonferroni
multiple test correction) for multi-group compari-
sons. Two-group and two-sample comparisons were
performed using Welch’s t-test and Fisher’s exact
t-test, respectively (two-sided with Bonferroni cor-
rection). We compiled a de-identified metadata table
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containing all of the clinical and demographic data
for each infant in this study (Supplementary Table
1). We then used a generalized linear regression
model (GLM) to examine the contribution of seven
measurable features from the patient demographic
data ('mode of birth', 'age at introduction of solid
foods', 'age at initial sampling', 'sex', 'body weight',
'duration of exclusive breastfeeding’ and ‘health
status’ (that is, healthy or CMA)) on the bacterial
abundance of the differentially abundant bacterial
families and strains as predicted by oligotyping. A
GLM model was constructed and validated using
rms and ResourceSelection (Lele, 2009) packages,
respectively. We modeled bacterial abundances
using a binomial distribution with a logit link
function. To examine whether fecal butyrate levels
correlated with bacterial diversity (Shannon diver-
sity index) and evenness (Pielou’s evenness index)
and oligotype abundance patterns across multiple
groups (that is, healthy, CMA, EHCF and EHCF-
LGG), we calculated the Spearman correlation using
the cor.test function implemented in R (http://www.
r-project.org/).
Determination of fecal butyrate concentration
Frozen feces weighing 1 g were diluted with saline,
vortexed and centrifuged at 13 000 r.p.m. for 10min
in 2-ml tubes. The supernatants were filtered
(0.45 μm) and used as the fecal extracts, which were
stored at − 20 °C until analysis. To determine fecal
butyrate concentration, frozen fecal extracts were
acidified with 20 μl 85% phosphoric acid and 0.5ml
ethyl acetate, mixed, centrifuged at 14 000 r.p.m. for
1 h and extracted in duplicate. A quantity of the
pooled extract containing the acidified butyrate was
transferred into a 2-ml glass vial and loaded onto an
Agilent Technologies (Santa Clara, CA, USA) 7890
gas chromatograph (GC) system with automatic
loader/injector. The GC column was an Agilent
J&W DB-FFAP (Agilent Technologies) with the
length 30m, internal diameter 0.25mm and film
thickness 0.25 μm. The GC was programmed to
achieve the following run parameters: initial tem-
perature 90 °C, hold 0.5min, ramp 20 °Cmin− 1, final
temperature 190 °C, total run time 8.0min, gas flow
7.7mlmin− 1 split less to maintain 3.26 p.s.i. column
head pressure, septum purge 2.0mlmin− 1. Detection
was achieved using a flame ionization detector.
Peaks were identified using a mixed external
standard and quantified by peak height/internal
standard ratio.
Results
The gut microbiota of cow’s milk allergic infants
exhibits significantly increased diversity and altered
composition
A fecal sample was obtained before diet therapy from
19 patients with IgE-mediated CMA. During the same
study period, fecal samples were also obtained from
20 age, sex and body weight-matched healthy infants
enrolled in a vaccination program. All study subjects
were breastfed for o1 month after birth and were
still receiving a formula containing cow’s milk
proteins at the time of enrollment and first fecal
sampling. A second fecal sample was obtained from
each of the CMA infants after 6 months of treatment
with EHCF with or without supplementation with
LGG. The demographic and clinical characteristics
of the study population are summarized in Table 1.
A metadata table containing all of the demographic
and clinical information for each patient in this
study is provided in Supplementary Table 1. To
compare the fecal microbiota of healthy and CMA
infants, we generated 1.7 million 16S rRNA V4
amplicon sequences, which following quality con-
trol, clustered into 592 OTUs (97% nucleotide
identity). Ordination and classification independent
analyses of overall bacterial community structure
demonstrated that allergic infants were significantly
more diverse than age-matched healthy controls
(Shannon’s index, healthy=1.7±0.8 vs CMA=2.6±0.4;
Figure 1a), and also significantly more even (Pielou’s
Table 1 Demographic and clinical characteristics of the study population
Healthy subjects Patients with IgE-mediated CMA
Treated with EHCF Treated with EHCF+LGG
N 20 7 12
Male, n (%) 11 (55.0) 4 (57.1) 9 (75.0)
Age, months ( ± s.d.) 4.2 (1.1) 4 (0.8) 4.3 (1.3)
Weight, g ( ± s.d.) 6937.5 (793.2) 5607.1 (480.8) 6366.7 (1074.1)
Vaginal delivery, n (%) 15 (75) 4 (57.1) 7 (58.3)
Duration of exclusive breastfeeding, days ( ± s.d.) 14.4 (4.5) 14.8 (5.4) 15.2 (3.1)
Age of solid food introduction, months ( ± s.d.) 4 (0.2) 4.1 (0.4) 4.1 (0.3)
Symptoms at the CMA onset
Vomiting, n (%) — 4 (57.1) 8 (66.7)
Urticaria/angioedema, n (%) — 3 (42.9) 4 (33.3)
Cough/wheezing, n (%) — 1 (14.3) 3 (25.0)
Abbreviations: CMA, cow’s milk allergy; EHCF, extensively hydrolyzed casein formula; LGG, Lactobacillus rhamnosus GG.
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evenness; healthy = 0.52 ± 0.2 vs CMA=0.6 ±0.3;
Figure 1b). Bacterial 16S rRNA abundance was
similar in all samples (Figure 1c).
Taxonomic assignment revealed marked differ-
ences between healthy and allergic infants. CMA
infants had a significant reduction in Bifidobacter-
iaceae, Streptococcaceae, Enterobacteriaceae and
Enterococcaceae, and were significantly enriched
for Ruminococcaceae (16%) and Lachnospiraceae
(20.5%; Figure 1d). The CMA infant gut microbiota
comprised 73% Bacteroidetes and Firmicutes taxa,
which are also known to dominate in the adult gut
(The Human Microbiome Project Consortium, 2012).
Genus-level analysis revealed a significant enrich-
ment in CMA infant samples of Ruminococcus and
Faecalibacterium, and a significant reduction in
Bifidobacterium and Escherichia (Welch’s t-test)
compared with healthy samples (Supplementary
Table 2).
To examine whether these significant differences
could be explained by demographic variables, we
applied a GLM for seven features (Supplementary
Table 1) fitted against the relative abundance of the
significantly different taxa. Health status (that is,
healthy or CMA) was the single largest significant
contributor to the differential abundance of Lach-
nospiraceae (P=5.74e− 05; Figure 1e), Ruminococ-
caceae (P=0.00144; Supplementary Figure S1A),
Enterobacteriaceae (P=0.0003; Supplementary
Figure S1B) and Streptococcaceae (P=0.00198;
Supplementary Figure S1C). It was also the second
largest contributor to Bifidobacteriaceae (P=0.0034,
Supplementary Figure S1D). Mode of birth and
gender did not significantly contribute to these
Figure 1 Significantly diverse bacterial community dynamics across cow’s milk allergy and its treatment. (a) Shannon diversity,
(b) Pielou’s evenness and (c) bacterial load in fecal samples from each healthy (n=20) or age-matched pre-treatment cow’s milk allergic
(CMA, n=18–19) patients at diagnosis. (d) Family level differential abundance across healthy, CMA pre-treatment and treated groups, as
computed by MetagenomeSeq. Families depicted are those determined to be differentially abundant. (e) Generalized linear model fitting of
patient demographic information across relative abundance of family Lachnospiraceae. Parallel x axis represents the relative contribution
value of every factor, as predicted by the GLM model. *Po0.05, **Po0.0001, by two-sided t-test or by GLM model.
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differences. However, body weight and age at initial
sampling were significantly associated with the
abundance of Enterobacteriaceae (Po0.0034,
Supplementary Figure S1B) and Bifidobacteriaceae
(Po0.00633, Supplementary Figure S1D), respec-
tively. We validated the GLM model by fitting these
features against genus-level abundances for Faecali-
bacterium, (Po0.0001, Supplementary Figure S2A),
Ruminococcus (Po0.0029, Supplementary Figure
S2B) Escherichia (Po0.0071, Supplementary
Figure S2C) and Bifidobacterium (Po0.0031,
Supplementary Figure S2D). These observations
suggested that CMA, more than any other measured
demographic variable, was the most important factor
affecting the significantly different components of
the gut microbiome.
Treatment with LGG-supplemented EHCF increases the
relative abundance of butyrate-producing bacteria and
fecal butyrate levels
Acquisition of tolerance was evaluated by double
blind placebo-controlled oral food challenge follow-
ing 12 months of treatment. In total, 5 out of 12
(42%) EHCF+LGG-treated infants developed
tolerance to cow’s milk proteins, whereas all (7/7)
of the EHCF-treated infants remained allergic
(P=0.1, Fisher’s exact test). We hypothesized that
EHCF+LGG promotes tolerance to cow’s milk
proteins in part by altering gut microbial community
structure. The fecal concentration of butyrate was
significantly greater in CMA infants treated with
LGG-supplemented EHCF, when compared with
those treated with EHCF alone (Figure 2a). When
we examined the samples from pre- and post-EHCF-
LGG treatment, Blautia, Roseburia and Coprococcus
were significantly enriched post-treatment (Po0.01;
Supplementary Table 2). However, Roseburia was
also significantly enriched post-treatment with EHCF
alone (Po0.01). There were also genus-level differ-
ences post-treatment between the EHCF and
EHCF-LGG groups; two-group analysis revealed
Roseburia and Anaerofustis as significantly enriched
in the Post-EHCF-LGG group (Supplementary Table 2).
The infants treated with EHCF+LGG had a
bi-modal distribution of butyrate production
post-treatment that was not seen in the children
treated with EHCF alone (Figure 2a). Bacteroideswas
significantly reduced in abundance in the high
butyrate group, whereas known butyrate producers,
Faecalibacterium, Blautia, Ruminococcus and Rose-
buria were significantly enriched in high butyrate
samples (Supplementary Table 2). In addition, the
alpha diversity and evenness of the microbial
community had a significantly positive correlation
with the quantity of butyrate post-treatment
(Supplementary Figures S3A and B).
Post-EHCF-LGG samples (n=12) were divided into
two groups; tolerant (n=5) and allergic (n=7).
Phylogenetically independent beta diversity analysis
(OTUs) clearly highlighted the inter- and intragroup
divergence between samples from tolerant and
allergic infants (Supplementary Figure S3C). Inter-
estingly, the tolerant group had a significantly
(Po0.0032, Welch’s t-test) greater average butyrate
concentration (12.52 ±0.32mmol kg− 1) than those
infants who remained allergic (10.32±0.3mmol kg−1).
In addition, 80% (4/5) of the tolerant samples
had higher butyrate concentrations with respect
to their paired samples in Pre-EHCF-LGG group
(Supplementary Figure S3B). However, although
tolerant sample 5 (T5) did show a significant
increase in butyrate following treatment, the quan-
tity of butyrate was still low (Supplementary Figure
S3B). Interestingly, we observed that tolerant sam-
ples with high levels (410mmol kg− 1) of fecal
butyrate (T1, 3 and 4) had a greater relative
abundance of Roseburia and Blautia compared with
samples with low levels (o6mmol kg− 1) of fecal
butyrate (T2 and 5; Supplementary Table 2).
Bacteroideswas enriched in the low level (o6mmol
kg− 1) butyrate samples. Two-group analysis (two-
sided Fisher’s exact t-test with Storey's false dis-
covery rate correction) was performed between
samples from tolerant and allergic infants before
and after EHCF-LGG treatment. There were no
significantly different genera before EHCF+LGG
treatment that identified infants who eventually
became tolerant to cow’s milk. In fact, the only
genus that was significantly different between
tolerant and allergic infants post-treatment with
EHCF+LGG was Oscillospira, which was enriched
in allergic samples (Supplementary Table 2). Owing
to its low abundance (o0.1%) we were not able to
perform subsequent oligotyping analysis (see below)
on Oscillospira.
Strain-level differences between tolerant and allergic
infants after treatment may have a role in tolerance
acquisition
Although only Oscillospira was significantly differ-
ent between tolerant and allergic infants, the fact that
Blautia, Roseburia and Coprococcus were signifi-
cantly different pre- and post-treatment with EHCF
+LGG (Figure 2b), and Blautia and Roseburia were
significantly enriched in samples from tolerant
infants with higher concentrations of fecal butyrate,
led us to hypothesize that tolerance may be asso-
ciated with the acquisition of specific strains of these
genera in tolerant individuals. We explored whether
there was any correlation between the abundance of
strains of these genera (100% nucleotide clustered
oligotypes), the increase in fecal butyrate concentra-
tion, and the acquisition of tolerance by the infants.
Oligotyping of Roseburia, Coprococcus and Blautia
(Figures 2c–e, respectively) revealed demarcations
among the treatment groups, especially across the
sample pairs representing CMA tolerant patients.
Significant differences in oligotype abundances
between samples were analyzed using a two-sample
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test (Fisher’s exact t-test with two-sided with
Bonferroni multiple test correction).
The four tolerant patients for whom oligotypes of
these genera could be detected are marked ‘T’ in
Figure 2 (T1–4). Roseburia OTU 26 disassociated
into 13 oligotypes that each presented different
patterns (Figure 2c), similar to Coprococcus OTU
40, which disassociated into four oligotypes
(Figure 2d). However, Blautia OTU 31, which
disassociated into seven oligotypes, was generally
at very low relative abundance, except in samples
from T3, where it had significantly lower relative
abundance post-treatment (Figure 2e).
The strain-level differential abundance patterns of
Roseburia and Coprococcus between the tolerant
and allergic groups, and between high and low
butyrate-producing subgroups of post-EHCF+LGG
samples were assessed. In addition, we also analyzed
how strain-level patterns varied across tolerant
samples before and after EHCF+LGG treatment.
Strikingly, the total strain profile of Roseburia
(R2 = 0.90) and Coprococcus (R2 = 0.94) was very
similar in both the tolerant and allergic groups
(Po0.001, Welch's t-test). However, Roseburia
oligotype 2 and Coprococcus oligotype 1 were
significantly enriched in the tolerant group
(Supplementary Table 2). The high and low
butyrate-producing groups revealed lower levels of
community (strain level) overlap, when compared
with the tolerant- allergic analysis (Roseburia
R2 = 0.64 and Coprococcus R2 = 0.63). The relative
abundance of Roseburia oligotype 2 and Coprococ-
cus oligotype 1 were still significantly enriched in
the high butyrate-producing group (Supplementary
Table 2). Interestingly, two-group analysis of tolerant
samples before and after treatment with EHCF+LGG
revealed a significant enrichment in Roseburia
oligotype 2 and Coprococcus oligotype 1 post-
treatment (Supplementary Table 2).
Fecal butyrate concentrations were positively cor-
related with the abundance of Roseburia oligotype 2
(R2 = 0.5, Po0.00061) and Coprococcus oligotype 1
(R2 = 0.36, Po0.18). Our data suggest that LGG
treatment enhances acquisition of tolerance to cow’s
milk, in part, by changing the strain-level community
structure of taxa with the potential to produce
butyrate. However, this strain-level correlation analy-
sis would be best validated with wider sampling size
including longitudinal time series events.
Discussion
The microbiota of CMA infants was significantly
more diverse than that of healthy controls. Bacterial
families characteristic of the healthy infant gut
Figure 2 Microbial community dynamics of fecal samples from cow’s milk allergic infants (CMA) before and after treatment. (a) Butyrate (n-
butyric acid) concentration in fecal samples from healthy patients (n=20), or from CMA patients before (CMA, n=19) and after treatment (post-
EHCF, n=7; post-EHCF+LGG, n=12). (b) Differential features (genera) selection analysis across healthy, CMA pre-treatment and treated groups
(EHCF and EHCF+LGG). Abundance matrix was processed using Kruskal–Wallis H-test (post hoc tests=Tukey Kramer, multiple test
correction=Bonferroni) with hierarchical clustering of both rows (genera; y axis; clusters are represented by color bars) and columns (samples; x
axis; clustering is performed with ‘average’ linkage, using Bray–Curtis’ distance for genera and ‘correlation’ for samples). The heatmap key
shows percent relative abundance. Oligotyping analysis reveals strain-level differential selection in (c) Roseburia, (d) Coprococcus and (d)
Blautia enriched across CMA and EHCF+LGG samples. Samples from EHCF+LGG-treated infants determined to be tolerant after double blind
placebo-controlled oral food challenge analysis are labeled as ‘T’. **Po 0.05, ***P o 0.001, by Kruskal–Wallis H-test.
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(notably, Enterobactericeae and Bifidobacteriaceae)
were significantly less abundant in the CMA gut, and
were replaced by an increase in Lachnospiraceae
and Ruminococcaceae, representing an emergence of
Firmicutes (particularly, Clostridiales). Blautia,
Roseburia and Coprococcus were significantly
enriched following treatment with EHCF and LGG,
but only one genus, Oscillospira, was significantly
different between infants that became tolerant and
those that remained allergic. However, most tolerant
infants showed a significant increase in fecal
butyrate levels, and those taxa that were significantly
enriched in these samples, Blautia and Roseburia,
exhibited specific strain-level demarcations between
tolerant and allergic infants.
Whether or not differences in the composition of
the microbiota (particularly abundance of Bifidobac-
teriaceae) precede the development of atopy, as
suggested by other reports (Bjorksten et al., 2001;
Kalliomaki et al., 2001a; Penders et al., 2013) is not
addressed in the current study, as the first fecal
sample was collected after the onset of CMA signs
and symptoms. However, as we have recently
reviewed, increasing evidence supports a role for
the microbiota in sensitization to food allergens,
where the use of antibiotics, anti-bacterial agents and
disruptions in fecal-associated community structure
correlate with an elevated risk of disease (Berni
Canani et al., 2015).
In the current report, the study cohort was selected
based upon a direct examination of fecal samples
obtained from CMA infants at diagnosis. The use of a
local Italian population with limited racial and
ethnic diversity and similar environmental influ-
ences (for example, diet) is likely to have minimized
interindividual variation in our study population.
Using an unbiased nonparametric statistical
approach, we demonstrated that allergic status was
the most significant correlative factor for the compo-
sition of the gut microbiota in CMA infants. Several
studies have suggested that providing combined
antenatal and postnatal supplementation with the
probiotic LGG to infants at risk for atopic diseases
protects against subsequent allergic sensitization
(Kalliomaki et al., 2001b; Kalliomaki et al., 2003;
Huurre et al., 2008). LGG may contribute to acquisi-
tion of tolerance to food allergens through the
modulation of cytokines that influence gut perme-
ability, thereby limiting the immune system’s expo-
sure to dietary allergens (Pohjavuori et al., 2004;
Ghadimi et al., 2008; Mileti et al., 2009; Donato et al.,
2010). Treatment with a LGG-supplemented formula
has previously been associated with alterations in
the composition of the gut microbiota (Cox et al.,
2010). Although in the present study it is not
possible to determine the mechanism by which
LGG treatment influences microbial community
composition and structure in these samples, other
work has begun to suggest potential ways by which
probiotics structure the host–gut ecosystem to affect
microbial ecology. For example, introduction of
Bacteroides fragilis into the gut environment of a
mouse model of autism influenced the microbial
community structure by producing a biofilm that
was potentially associated with the intestinal wall
(Hsiao et al., 2013). This interaction is likely to have
shaped the microbial community by altering the host
immune response, changing the metabolic interac-
tion space in the gut, and altering the physical
environment.
Although further analysis will be required to
elucidate the mechanisms for their selection the
observed increase in the relative abundance of
specific strains of Roseburia and Coprococcus in
CMA infants successfully treated with EHCF-LGG is
nonetheless intriguing. These genera belong to the
Clostridiales, which comprise a large, heterogeneous
bacterial order (Nava and Stappenbeck, 2011;
Nagano et al., 2012). Short chain fatty acid (SCFA)
production, particularly that of butyrate, is enriched
within Clostridium cluster XIVa, (Sokol et al., 2008;
Louis and Flint, 2009; Sokol et al., 2009; Miquel
et al., 2013; Van den Abbeele et al., 2013). Butyrate is
the preferred energy source for colonocytes and is
often considered a sensor of intestinal health (Miquel
et al., 2013). Both bacterial abundance and SCFA
production are sensitive to dietary manipulation
(Duncan et al., 2007; Louis and Flint, 2009; De
Filippo et al., 2010). Indigenous clostridial strains
from clusters IV, XIVa and XVIII isolated from both
mice (Atarashi et al., 2011) and humans (Atarashi
et al., 2013) are among the most potent inducers of
Foxp3+ regulatory T cells in the colonic lamina
propria. Bacteria-produced SCFAs critically regulate
both the proportions and functional capabilities of
colonic regulatory T cells (Arpaia et al., 2013; Smith
et al., 2013) and this phenomenon has been
specifically linked to butyrate production by
spore-forming Clostridiales (Furusawa et al., 2013).
We have recently described a novel mechanism by
which Clostridia regulate innate lymphoid cell
function to alter epithelial permeability and reduce
allergen uptake into the systemic circulation (Stefka
et al., 2014). Preliminary data from our laboratory
links butyrate, but not other SCFAs, to regulation of
epithelial barrier function (Feehley et al., personal
communication). It will be of interest to examine
whether the expansion of specific clostridial strains
in infants treated with EHCF+LGG accelerates
acquisition of tolerance by fortifying epithelial
barrier function.
Treatment of CMA infants with extensively hydro-
lyzed casein formula containing LGG resulted in the
enrichment of specific strains of bacteria that are
associated with butyrate production (Ferrario et al.,
2014). The strain-level associations were not con-
served, however, between patients who became
tolerant, which suggests that the extraordinary
degree of interpersonal strain-level bacterial diver-
sity observed in human populations (for example
Raveh-Sadka et al., 2015) may result in many
different ‘tolerance-associated’ microbial profiles.
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Our findings will inform the development of effec-
tive strategies to prevent or treat food allergy based
on modulation of the intestinal microbiota.
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